- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
International Isotopes shuffles management team
Following the retirement of chairman and treasurer Ira Lon Morgan, radiopharmaceutical manufacturer International Isotopes has made some additional changes to its senior management team (SCAN 12/15/99). The Denton, TX-based company, which is in
Following the retirement of chairman and treasurer Ira Lon Morgan, radiopharmaceutical manufacturer International Isotopes has made some additional changes to its senior management team (SCAN 12/15/99). The Denton, TX-based company, which is in the process of transitioning to fully commercial operations, announced that newly appointed CEO David Camp has taken on the additional responsibilities of president. Camp replaces former president Carl Seidel, who has left the company.
In addition, Bryce Drake has joined International Isotopes as director of support services. Drake takes over the position from George Butterworth, who has stepped into the new position of director of radioisotope production. Also new to the management team is Scott Colpitts, who has replaced Gaylord King as director of radiopharmaceutical manufacturing. King will continue to work closely with the firm.
In other company news, the Bureau of Radiation Control of the Texas Department of Health approved amendments to International Isotopes operational and development licenses that will allow the company to produce commercial quantities of radioisotopes for use in nuclear medicine procedures.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
